Effect of combination ezetimibe and high-dose simvastatin vs simvastatin alone on the atherosclerotic process in subjects with heterozygous familial hypercholesterolemia (the ENHANCE trial)

Trial Profile

Effect of combination ezetimibe and high-dose simvastatin vs simvastatin alone on the atherosclerotic process in subjects with heterozygous familial hypercholesterolemia (the ENHANCE trial)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Atherosclerosis; Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 15 Jan 2008 Primary endpoint not met; results reported by Merck/Schering-Plough.
    • 20 Nov 2007 Data are being analysed; results are expected to be presented at the American College of Cardiology meeting in 2008.
    • 24 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top